The Claim
In mice with diet-induced obesity, semaglutide reduces whole-body energy expenditure to the same extent as caloric restriction, despite greater fat loss, indicating that reduced metabolic rate is a consequence of lean mass loss rather than a direct pharmacological effect of semaglutide.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, semaglutide lowers total energy use as much as eating fewer calories, even though it causes more fat loss; this suggests the drop in metabolism is due to loss of lean tissue, not the drug itself.
See the scientific wording
In mice with diet-induced obesity, semaglutide reduces whole-body energy expenditure to the same extent as caloric restriction, despite greater fat loss, suggesting that reduced metabolic rate is a consequence of lean mass loss rather than a direct drug effect.
When the body gets less food, it breaks down muscle tissue to save energy. Less muscle means the body burns fewer calories overall. This happens whether the food reduction comes from eating less or from a drug that cuts appetite. The muscle loss is not caused by the drug itself, but by the lack of calories.
What the research says
1 studyIn obese mice, both semaglutide and eating less caused the same drop in muscle and strength, but semaglutide lost more fat. This suggests the body burns fewer calories because it lost muscle—not because the drug directly slows metabolism.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.